ReviewExpert opinion on drug metabolism & toxicology2013
Pharmacogenetics of antipsychotics: recent progress and methodological issues.
Review in Expert opinion on drug metabolism & toxicology, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 23 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
23 citing papers in PubMed, 1 synthesis or guideline pooled it, 60 citations in OpenAlex.
- The promise of biological markers for treatment response in first-episode psychosis: a systematic review.Schizophrenia bulletin · 2015Pooled it
- Early Efficacy of Antipsychotic Medications at Week 2 Predicts Subsequent Responses at Week 6 in a Large-scale Randomized Controlled Trial.Current neuropharmacology · 2023Trial
- Effect of Damaging Rare Mutations in Synapse-Related Gene Sets on Response to Short-term Antipsychotic Medication in Chinese Patients With Schizophrenia: A Randomized Clinical Trial.JAMA psychiatry · 2018Trial
- Exploring Mitochondrial Autophagy Dysregulation in Osteosarcoma: Its Implications for Prognosis and Targeted Therapy.Combinatorial chemistry & high throughput screening · 2026Article
- Pharmacogenetics of Antipsychotic Treatment in Schizophrenia.Methods in molecular biology (Clifton, N.J.) · 2022Article
- Treatment resistant schizophrenia: Clinical, biological, and therapeutic perspectives.Neurobiology of disease · 2019Review
- ThePharmacogenomics · 2019Review
- Genetics of clozapine-associated neutropenia: recent advances, challenges and future perspective.Pharmacogenomics · 2019Review
- The Potential Role of Regulatory Genes (Frontiers in genetics · 2019Article
- Recent Progress in Pharmacogenomics of Antipsychotic Drug Response.Current psychiatry reports · 2018Review
- Genetics of Schizophrenia: Ready to Translate?Current psychiatry reports · 2017Review
- Clozapine as a Model for Antipsychotic Development.Neurotherapeutics : the journal of the American Society for Experimental NeuroTherapeutics · 2017Review
- ENIGMA and the individual: Predicting factors that affect the brain in 35 countries worldwide.NeuroImage · 2017Review
- Significant weight loss following clozapine use, how is it possible? A case report and review of published cases and literature relevant to the subject.Therapeutic advances in psychopharmacology · 2016Review
- Pharmacogenetic tests for antipsychotic medications: clinical implications and considerations.Dialogues in clinical neuroscience · 2016Review
- Genetic determinants of antithyroid drug-induced agranulocytosis by human leukocyte antigen genotyping and genome-wide association study.Nature communications · 2015Article
- Current and emergent treatments for symptoms and neurocognitive impairment in schizophrenia.Current treatment options in psychiatry · 2015Article
- Recent genetic findings in schizophrenia and their therapeutic relevance.Journal of psychopharmacology (Oxford, England) · 2015Review
- Schizophrenia as a disorder of molecular pathways.Biological psychiatry · 2015Review
- Pharmacogenetics of antipsychotic-induced movement disorders as a resource for better understanding Parkinson's disease modifier genes.Frontiers in neurology · 2015Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors at 1 institution in 1 country.
Funding
Abstract
introductionAntipsychotic drug is the mainstay of treatment for schizophrenia, and there are large inter-individual differences in clinical response and side effects. Pharmacogenetics provides a valuable tool to fulfill the promise of personalized medicine by tailoring treatment based on one's genetic markers. AREAS COVERED: This article reviews the recent progress in pharmacogenetic research of antipsychotic drugs since 2010, focusing on two areas: antipsychotic-induced weight gain and clozapine-induced agranulocytosis. The article also provides discussion on the important methodological issues in this area of research. The specific aim of this article is to provide the reader with up-to-date evidence in pharmacogenetic research, and for them to gain familiarity to the issues and challenges facing the field. EXPERT OPINION: Pharmacogenetic studies of antipsychotic drugs are promising despite many challenges. Recent advances as reviewed in this article push the field closer to routine clinical utilization of pharmacogenetic testing. Progress in genomic technology and bioinformatics, larger sample sizes, better phenotype characterization, and careful consideration of study design issues will help to elevate antipsychotic pharmacogenetics to its next level.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.